Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration

Retina

Volumn 30, Issue 7, 2010, Pages 1034-1038

  Sawada, Osamu ^a   Miyake, Taichiro ^a   Kakinoki, Masashi ^a   Sawada, Tomoko ^a   Kawamura, Hajime ^a   Ohji, Masahito ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; AQUEOUS HUMOR; CHOROIDAL NEOVASCULARIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77954722637     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181ce74c8     Document Type: Article

References (21)

1. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934.
2. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37: 855-868.
3. Aiello AP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.
4. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular growth endothelial factor prevents retinal ischemiaassociated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
5. Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 1998;39:180-188.
6. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000;156:697-707.
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
8. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
9. BrownDM,Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-macular degeneration. Two-year results of the ANCHOR study. Ophthalmology 2009; l16:57-65.e5.
10. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, GiustMJ. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006;113:363-372.
11. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agemacular degeneration. Retina 2006;26:383-390. (Pubitemid 44197628)
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
13. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007;125:1363-1366.
14. ChanWM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008;28:1308-1313.
15. Presta LG, Chen H, O'Connor SJ, et al. Humanization of antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599.
16. Chen Y,Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an af-finity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-881.
17. Ruckman J, Green LS, Beeson J, et al. 2/-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-20567.
18. Saed GM, Collins KL, Diamond MP. Transforming growth factors b1, b2 and b3 and their receptors are differentially expressed in human peritoneal fibroblasts in response to hypoxia. Am J Reprod Immunol 2002;48:387-393.
19. Catena R, Muniz-Medina V, Moralejo B, et al. Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis. Int J Cancer 2007;120:2096-2109.
20. Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit in expand tumor vasculature. Mol Cell Biol 2000;20:7282-7291.
21. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-489.